Inhibrx Biosciences announced a decisive legal victory in a trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation. This verdict confirms the Company's adherence to ethical standards and innovation in scientific research.
I-Mab had initiated the lawsuit on March 1, 2022, alleging improper access and use of proprietary information by Inhibrx and its Chief Scientific Officer, Brendan Eckelman. The jury found no basis for these claims, validating Inhibrx's independent development processes.
This outcome allows Inhibrx to focus on delivering therapies to patients without the distraction of ongoing legal proceedings. The company's scientific achievements were demonstrated to be the result of its own hard work and advanced capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.